Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Additional Nasdaq Staff Determination; Nasdaq Hearings Panel Consideration

On September 25, 2026, Silexion Therapeutics Corp (the "Company" or "Silexion") received a letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the 30 consecutive business days preceding the letter, the closing bid price of the Company's ordinary shares, par value $0.135 per share ("ordinary shares"), was below the minimum $1.00 per share required for continued listing on The Nasdaq Stock Market LLC under Nasdaq Listing Rule 5550(a)(2) (the "bid price deficiency"). The Staff indicated in the letter that the Nasdaq hearings panel would consider the bid price deficiency in its decision as to whether to enable the Company to remain listed on the Nasdaq Capital Market.

The Nasdaq letter has no immediate effect on the listing of the ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol "SLXN" at this time. Additionally, the Staff's letter has no impact on the Company's listed warrants to purchase ordinary shares, which will continue to trade as usual on the Nasdaq Capital Market under the symbol "SLXNW".